Bidlingmaier M - Search Results

1

Cushing's syndrome: a model for sarcopenic obesity.

Drey M, Berr CM, Reincke M, Fazel J, Seissler J, Schopohl J, Bidlingmaier M, Zopp S, Reisch N, Beuschlein F, Osswald A, Schmidmaier R. Drey M, et al. Among authors: bidlingmaier m. Endocrine. 2017 Sep;57(3):481-485. doi: 10.1007/s12020-017-1370-x. Epub 2017 Jul 12. Endocrine. 2017. PMID: 28702888

2

Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma.

Beuschlein F, Strasburger CJ, Siegerstetter V, Moradpour D, Lichter P, Bidlingmaier M, Blum HE, Reincke M. Beuschlein F, et al. Among authors: bidlingmaier m. N Engl J Med. 2000 Jun 22;342(25):1871-6. doi: 10.1056/NEJM200006223422504. N Engl J Med. 2000. PMID: 10861322 Free article. No abstract available.

3

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Gutt B, et al. Among authors: bidlingmaier m. Exp Clin Endocrinol Diabetes. 2005 Mar;113(3):139-44. doi: 10.1055/s-2005-837520. Exp Clin Endocrinol Diabetes. 2005. PMID: 15789272

4

Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.

Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Steffin B, et al. Among authors: bidlingmaier m. Eur J Endocrinol. 2006 Jul;155(1):73-8. doi: 10.1530/eje.1.02185. Eur J Endocrinol. 2006. PMID: 16793952 Clinical Trial.

5

Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps.

Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Schirpenbach C, et al. Among authors: bidlingmaier m. Clin Chem. 2006 Sep;52(9):1749-55. doi: 10.1373/clinchem.2006.068502. Epub 2006 Jul 20. Clin Chem. 2006. PMID: 16858077

6

[Diagnosis of primary hyperaldosteronism].

Diederich S, Bidlingmaier M, Quinkler M, Reincke M. Diederich S, et al. Among authors: bidlingmaier m. Med Klin (Munich). 2007 Jan 15;102(1):16-21. doi: 10.1007/s00063-007-1002-y. Med Klin (Munich). 2007. PMID: 17221347 Review. German.

7

Preanalytical stability of adrenocorticotropic hormone depends on time to centrifugation rather than temperature.

Reisch N, Reincke M, Bidlingmaier M. Reisch N, et al. Among authors: bidlingmaier m. Clin Chem. 2007 Feb;53(2):358-9. doi: 10.1373/clinchem.2006.080622. Clin Chem. 2007. PMID: 17259248 No abstract available.

8

Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.

Roemmler J, Bidlingmaier M, Schopohl J. Roemmler J, et al. Among authors: bidlingmaier m. Pituitary. 2010;13(1):89-93. doi: 10.1007/s11102-008-0131-5. Pituitary. 2010. PMID: 18498055

9

Serum leptin and ghrelin levels in active and inactive acromegalic patients during an oral glucose tolerance test.

Roemmler J, Otto B, Steffin B, Bidlingmaier M, Schopohl J. Roemmler J, et al. Among authors: bidlingmaier m. Exp Clin Endocrinol Diabetes. 2009 Mar;117(3):135-41. doi: 10.1055/s-2008-1078739. Epub 2008 Jun 17. Exp Clin Endocrinol Diabetes. 2009. PMID: 18561093 Clinical Trial.

10

The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.

Roemmler J, Steffin B, Gutt B, Sievers C, Bidlingmaier M, Schopohl J. Roemmler J, et al. Among authors: bidlingmaier m. Growth Horm IGF Res. 2009 Jun;19(3):245-51. doi: 10.1016/j.ghir.2008.11.002. Epub 2008 Dec 23. Growth Horm IGF Res. 2009. PMID: 19109045

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

360 results

Search Page

Filters